A Modeling Study of the Cost Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom
Value in Health
MetadataShow full item record
Wilson, E. C., Usher-Smith, J., Emery, J., Corrie, P., & Walter, F. M. A Modeling Study of the Cost Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom. Value in Health https://doi.org/10.1016/j.jval.2017.11.009
Background: Population-wide screening for melanoma is unlikely to be cost-effective. Nevertheless, targeted surveillance of high-risk individuals may be. Objectives: To estimate the cost effectiveness of various surveillance strategies in the UK population, stratified by risk using a simple self-assessment tool scoring between 0 and 67. Methods: A decision model comparing alternative surveillance policies from the perspective of the UK National Health Service over 30 years was developed. The strategy with the highest expected net benefit for each risk score was identified, resulting in a compound risk-stratified policy describing the most cost-effective population-wide strategy. The overall expected cost and quality-adjusted life-years (QALYs), the incremental cost-effectiveness ratio, and associated uncertainty were reported. Results: The most cost-effective strategy is for those with a Williams score of 15 to 21 (relative risk [RR] of 0.79–1.60 vs. a mean score of 17 in the United Kingdom) to be offered a one-off full-body skin examination, and for those with a score of 22 or more (RR 1.79+) to be enrolled into a quinquennial monitoring program, rising to annual recall for those with a risk score greater than 43 (RR 20.95+). Expected incremental cost would be £164 million per annum (~0.1% of the National Health Service budget), gaining 15,947 additional QALYs and yielding an incremental cost-effectiveness ratio of £10,199/QALY gained (51.3% probability <£30,000). Conclusions: The risk-stratified policy would be expensive to implement but cost-effective compared with typical UK thresholds (£20,000–£30,000/QALY gained), although decision uncertainty is high. Phased implementation enrolling only higher risk individuals would be substantially less expensive, but with consequent foregone health gain.
cost effectiveness, decision modeling, economic evaluation, melanoma, screening
This study was supported in part by F. M. Walter’s Clinician Scientist Award from the National Institute for Health Research (NIHR) (grant no. RG 68235). E. C. F. Wilson is funded by the NIHR Cambridge Biomedical Research Centre. J. Usher-Smith was funded by an NIHR Clinical Lectureship. J. Emery is funded by an National Health and Medical Research Council (NHMRC) Practitioner Fellowship. The analysis was performed using the Darwin Supercomputer of the University of Cambridge High Performance Computing Service (http://www.hpc.cam.ac.uk/), provided by Dell, Inc., using Strategic Research Infrastructure Funding from the Higher Education Funding Council for England and funding from the Science and Technology Facilities Council.
Embargo Lift Date
External DOI: https://doi.org/10.1016/j.jval.2017.11.009
This record's URL: https://www.repository.cam.ac.uk/handle/1810/273216